

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ZJ

中基長壽科學

ZHONG JI LONGEVITY SCIENCE

Zhong Ji Longevity Science Group Limited

中基長壽科學集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

**COMPLETION OF SUBSCRIPTION OF
NEW SHARES UNDER GENERAL MANDATE**

Reference is made to the announcement (the “**Announcement**”) of Zhong Ji Longevity Science Group Limited (the “**Company**”) dated 30 May 2024 in relation to the Subscription of new Shares under General Mandate. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that all the Conditions Precedent set out in the Subscription Agreements had been fulfilled and the closing of the Subscription took place on 6 June 2024. Upon the closing of the Subscription, an aggregate of 91,088,258 Subscription Shares, representing approximately 16.67% of the issued share capital of the Company as at the date of this announcement as enlarged by the Subscription, have been allotted and issued to the Subscribers at the Subscription Price of HK\$0.215 per Subscription Share. The aggregate gross proceeds from the Subscription amounted to approximately HK\$19,584,000.

The aggregate net proceeds from the Subscription, after deduction of relevant costs and expenses, amounted to approximately HK\$19,384,000. The Company intends to apply the net proceeds from the Subscription as to 60.0% thereof for the expansion of the existing longevity science business and the new biomedical products trading business. The remaining 40.0% of the net proceeds will be allocated for general working capital for payment of staff costs, rental expenses and legal and professional expenses.

EFFECTS ON SHAREHOLDING STRUCTURE

The table below sets out the shareholding structure of the Company before and after the Subscription:

Name of Shareholders	Before the Completion of the Subscription		Upon the Completion of the Subscription	
	Number of Shares	Approximate %	Number of Shares	Approximate %
Substantial shareholders				
Mr. Butani Pap Udham	50,530,000	11.09%	50,530,000	9.24%
Mr. Chainrai Balram	50,000,000	10.98%	50,000,000	9.15%
Director				
Mr. Yan Li	49,143,517	10.79%	49,143,517	8.99%
Public shareholders				
Mr. So Hoi Wing, Jackson	30,000,000	6.59%	30,000,000	5.49%
Ms. Yan Zhen (Subscriber A)	—	—	30,232,558	5.53%
Mr. Wang Jianyong (Subscriber B)	—	—	46,511,628	8.51%
Mr. Zhang Yi (Subscriber C)	—	—	14,344,072	2.63%
Other public Shareholders	<u>275,767,774</u>	<u>60.55%</u>	<u>275,767,774</u>	<u>50.46%</u>
Total	<u><u>455,441,291</u></u>	<u><u>100%</u></u>	<u><u>546,529,549</u></u>	<u><u>100%</u></u>

By order of the Board
Zhong Ji Longevity Science Group Limited
Yan Yifan
Chief Executive Officer

Hong Kong, 6 June 2024

As at the date of this announcement, the Directors are:

Executive Directors

Mr. Yan Li (*Chairman*)
Mr. Yan Yifan (*Chief Executive Officer*)
Mr. Li Xiaoshuang
Ms. Cao Xie Qiong

Independent non-executive Directors

Mr. Lee See Barry
Mr. Wang Ning
Prof. Huang Cibo

Non-executive Directors

Dr. He Yiwu
Mr. Lyn Changsheng

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.